A 55-year-old man presents with gradually increasing shortness of breath and leg swelling over the past month. He has also noticed orthopnea and paroxysmal nocturnal dyspnea. He takes simvastatin for hypercholesterolemia and hydrochlorothiazide for hypertension. Blood pressure is 140/90 mm Hg; there is mild jugular venous distension, soft bibasilar crackles, an S3 gallop, and minimal pedal edema. An echocardiogram shows left ventricular ejection fraction (LVEF) of 40% without segmental wall-motion abnormality. The patient desires to keep medications to a minimum What change in his management would you recommend at this time?
A 55-year-old man presents with gradually increasing shortness of breath and leg swelling over the past month. He has also noticed orthopnea and paroxysmal nocturnal dyspnea. He takes simvastatin for hypercholesterolemia and hydrochlorothiazide for hypertension. Blood pressure is 140/90 mm Hg; there is mild jugular venous distension, soft bibasilar crackles, an S3 gallop, and minimal pedal edema. An echocardiogram shows left ventricular ejection fraction (LVEF) of 40% without segmental wall-motion abnormality. The patient desires to keep medications to a minimum What change in his management would you recommend at this time?
💡 Explanation
**Core Concept**
The patient is presenting with signs and symptoms of heart failure with reduced ejection fraction (HFrEF), characterized by symptoms such as orthopnea, paroxysmal nocturnal dyspnea, and S3 gallop, along with echocardiogram findings of reduced LVEF. The goal of management is to improve symptoms, reduce hospitalizations, and improve survival.
**Why the Correct Answer is Right**
The patient's symptoms and echocardiogram findings are consistent with HFrEF. The use of ACE inhibitors or ARBs has been shown to improve survival and reduce hospitalizations in patients with HFrEF. Beta-blockers also reduce morbidity and mortality in these patients. However, the patient desires to keep medications to a minimum. In this case, the addition of a mineralocorticoid receptor antagonist (MRA) such as spironolactone or eplerenone would be beneficial. MRAs have been shown to reduce morbidity and mortality in patients with HFrEF, particularly in those with severe symptoms.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because ACE inhibitors or ARBs are already being used in the management of heart failure, and adding another ACE inhibitor or ARB would not be beneficial.
**Option B:** This option is incorrect because beta-blockers are already being used in the management of heart failure, and adding another beta-blocker would not be beneficial.
**Option C:** This option is incorrect because digoxin is typically used in patients with atrial fibrillation or those who are resistant to other medical therapy, and it would not be the first-line treatment in this case.
**Option D:** This option is incorrect because diuretics are already being used in the management of heart failure, and adding a diuretic would not address the underlying pathophysiology of the disease.
**Clinical Pearl / High-Yield Fact**
In patients with HFrEF, the use of MRAs such as spironolactone or eplerenone can reduce morbidity and mortality, particularly in those with severe symptoms. This is because MRAs have anti-fibrotic effects and can reduce fluid overload.
**Correct Answer:** C.
✓ Correct Answer: B. Add an ACE inhibitor and a beta-blocker
📤 Share this MCQ
Share Card Preview
👆 1080x1080 square card — fills the full width in WhatsApp and Telegram